
Astal Laboratories (ASTALLTD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
253.3M
Gross Profit
38.6M
15.24%
Operating Income
30.4M
11.99%
Net Income
20.9M
8.25%
EPS (Diluted)
₹1.74
Balance Sheet Metrics
Total Assets
633.4M
Total Liabilities
273.5M
Shareholders Equity
359.9M
Debt to Equity
0.76
Cash Flow Metrics
Revenue & Profitability Trend
Astal Laboratories Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 642.3M | 236.5M | 34.3M | 0 | 0 |
Cost of Goods Sold | 484.8M | 213.4M | 33.5M | 0 | 0 |
Gross Profit | 157.5M | 23.1M | 735.0K | 0 | 0 |
Gross Margin % | 24.5% | 9.8% | 2.1% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 1.3M | 2.1M | 231.0K | 157.0K | 278.5K |
Other Operating Expenses | 13.7M | 4.2M | 1.2M | 983.0K | 829.0K |
Total Operating Expenses | 14.9M | 6.3M | 1.4M | 1.1M | 1.1M |
Operating Income | 125.5M | 10.9M | -1.5M | -2.2M | -1.9M |
Operating Margin % | 19.5% | 4.6% | -4.3% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 1.3M | 134.0K | 1.8M | 2.1M | 2.0M |
Interest Expense | 7.0M | 108.0K | 0 | 0 | 0 |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 119.8M | 10.9M | 321.0K | -171.0K | 81.1K |
Income Tax | 30.5M | 3.0M | 156.0K | 1.0K | 20.9K |
Effective Tax Rate % | 25.5% | 27.8% | 48.6% | 0.0% | 25.8% |
Net Income | 89.3M | 7.8M | 165.0K | -172.0K | 60.2K |
Net Margin % | 13.9% | 3.3% | 0.5% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | 129.0M | 11.3M | 402.0K | -2.0M | -1.8M |
EPS (Basic) | ₹9.08 | ₹1.55 | ₹0.04 | ₹-0.04 | ₹0.02 |
EPS (Diluted) | ₹8.04 | ₹1.55 | ₹0.04 | ₹-0.04 | ₹0.02 |
Basic Shares Outstanding | 9830070 | 5050950 | 3974070 | 3974070 | 3974070 |
Diluted Shares Outstanding | 9830070 | 5050950 | 3974070 | 3974070 | 3974070 |
Income Statement Trend
Astal Laboratories Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 17.3M | 60.8M | 844.0K | 183.0K | 312.9K |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 276.6M | 158.2M | 31.7M | 0 | - |
Inventory | 147.6M | 10.6M | 0 | 0 | - |
Other Current Assets | 14.9M | 37.8M | 28.6M | - | 12.0K |
Total Current Assets | 456.4M | 267.3M | 61.1M | 970.0K | 51.8M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 568.0K | 545.0K | 545.0K | 546.0K |
Goodwill | - | 0 | 0 | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -1.0K | 1.0K | 2.0K | 1.0K | 666.5K |
Total Non-Current Assets | 177.0M | 98.9M | 37.9M | 51.3M | 1.2M |
Total Assets | 633.4M | 366.1M | 99.1M | 52.3M | 53.1M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 107.7M | 115.2M | 37.9M | 0 | - |
Short-term Debt | 128.1M | 548.0K | 0 | 0 | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 31.8M | 4.4M | 2.4M | 679.0K | 694.8K |
Total Current Liabilities | 267.7M | 130.1M | 47.3M | 688.0K | 1.3M |
Non-Current Liabilities | |||||
Long-term Debt | 4.6M | 2.6M | 0 | - | - |
Deferred Tax Liabilities | 1.2M | 72.0K | 0 | - | - |
Other Non-Current Liabilities | - | -1.0K | - | - | - |
Total Non-Current Liabilities | 5.7M | 2.6M | 0 | 0 | 1.3M |
Total Liabilities | 273.5M | 132.7M | 47.3M | 688.0K | 2.6M |
Equity | |||||
Common Stock | 98.5M | 98.5M | 39.9M | 39.9M | 39.9M |
Retained Earnings | 107.0M | 17.8M | 9.9M | 9.8M | 9.9M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 359.9M | 233.4M | 51.8M | 51.6M | 51.8M |
Key Metrics | |||||
Total Debt | 132.7M | 3.1M | 0 | 0 | 0 |
Working Capital | 188.7M | 137.2M | 13.8M | 282.0K | 50.5M |
Balance Sheet Composition
Astal Laboratories Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 119.8M | 10.9M | 321.0K | -171.0K | 81.1K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -242.5M | -146.2M | -50.8M | 260.0K | -354.8K |
Operating Cash Flow | -117.0M | -135.5M | -52.3M | -2.0M | -2.3M |
Investing Activities | |||||
Capital Expenditures | -57.8M | -59.2M | 0 | 250.0K | 0 |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -57.7M | -59.2M | 1.0K | 250.0K | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 3.2M | 3.3M | 0 | 0 | 0 |
Debt Repayment | -547.0K | -174.0K | 0 | 0 | 0 |
Financing Cash Flow | 70.2M | 177.0M | 15.0M | 0 | 0 |
Free Cash Flow | -182.9M | -115.1M | -14.4M | -2.5M | -1.9M |
Net Change in Cash | -104.5M | -17.6M | -37.2M | -1.7M | -2.3M |
Cash Flow Trend
Astal Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
10.16
Price to Book
2.23
Price to Sales
1.17
PEG Ratio
0.43
Profitability Ratios
Profit Margin
12.33%
Operating Margin
11.14%
Return on Equity
24.80%
Return on Assets
14.09%
Financial Health
Current Ratio
1.70
Debt to Equity
36.86
Beta
-0.81
Per Share Data
EPS (TTM)
₹8.06
Book Value per Share
₹36.75
Revenue per Share
₹76.96
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
astalltd | 889.9M | 10.16 | 2.23 | 24.80% | 12.33% | 36.86 |
Vishal Mega Mart | 688.4B | 100.69 | 10.72 | 9.87% | 6.11% | 27.02 |
Shoppers Stop | 60.7B | 344.32 | 19.11 | 3.39% | 0.38% | 1,031.78 |
Spencer's Retail | 5.0B | -2.04 | -0.76 | 37.24% | -14.20% | -2.38 |
Osia Hyper Retail | 4.0B | 20.86 | 1.00 | 10.20% | 1.45% | 51.08 |
Future Retail | 1.3B | -0.04 | -0.10 | -291.62% | -52.09% | -12.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.